David Santamaría
ScholarGPS® ID: 55763446623459
Affiliation History
Discipline
Chemistry
Top Specialties
Cancer | Lung Cancer | Cell Cycle | Non-small-cell Lung Carcinoma
Metrics Summary
Publication Count
35
Predicted Citations
3,580
Predicted h-index
22
Ranking
Publications and Citation History
Publications based on Top Specialties
Types of Publication
- Publications
- Books
- Patents
- NIH/NSF
Add
Delete
|
---|
Cancer Treatment Reviews, volume 103 (2022). |
Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer (journal article) Cancers, volume 13, issue 19, pages 4734- (2021). |
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer (journal article) Trends in Cancer, volume 7, issue 5, pages 410-429 (2021). |
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas (journal article) Proceedings of the National Academy of Sciences, volume 117, issue 39, pages 24415-24426 (2020). |
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma (journal article) JCI Insight, volume 5, issue 15 (2020). |
Squamous differentiation requires G2/mitosis slippage to avoid apoptosis (journal article) Cell Death & Differentiation, volume 27, issue 8, pages 2451-2467 (2020). |
Meeting report – first discoidin domain receptors meeting (journal article) Journal of Cell Science, volume 133, issue 4 (2020). |
Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27 (journal article) Scientific Reports, volume 9, issue 1 (2019). |
Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer (journal article) Lung Cancer, volume 126 (2018). |
Cell Adhesion & Migration (2018). |
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS (journal article) Cell, volume 172, issue 4, pages 857-868.e15 (2018). |
Wild-type KRAS mediates growth inhibition and resistance to MEK inhibitors through dimerization with mutant KRAS in lung adenocarcinoma (journal article) Annals of Oncology, volume 28, issue suppl_5 (2017). |
A Braf kinase-inactive mutant induces lung adenocarcinoma (journal article) Nature, volume 548, issue 7666, pages 239-243 (2017). |
In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma (journal article) Oncogene, volume 36, issue 16, pages 2309-2318 (2017). |
DDR1 and Notch: a multifaceted synergy (journal article) Translational cancer research, volume 5, issue 7 (2016). |
DDR1 and Notch: a multifaceted synergy (journal article) Translational Cancer Research, volume 5, issue S7, pages S1551-S1553 (2016). |
Oncotarget, volume 7, issue 32 (2016). |
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma (journal article) Nature Medicine, volume 22, issue 3, pages 270-277 (2016). |
KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy (journal article) ESMO Open, volume 1, issue 5, pages e000076- (2016). |
Functional Reprogramming of Polyploidization in Megakaryocytes (journal article) Developmental Cell, volume 32, issue 2, pages 155-167 (2015). |